Dr. Jan Lundberg
Chair of Scientifc Advisory Board
Novel Drug Discovery and Development
Jan joined IAG in 2018 to chair IAG’s distinguished board of in-house scientists, imaging experts and academic collaborators and closely work with biotech and pharma partners. Jan's expertise and many years of experience are in the critical assessment of novel therapeutic agents and strategic positioning to maximize the chances of their success. Dr. Lundberg, a scientist with over 22 years of experience in global pharmaceutical R&D. Until recently he was heading R&D organization for Ely Lilly and previously – global research for AstraZeneca. He was involved with discovery of more than 200 candidate drugs and 22 approved products across multiple therapeutic areas, including immunology, oncology and neurology; he has been instrumental for the use of imaging cross therapeutic area projects including amyloid and tau PET imaging in Alzheimer’s dementia. His career began in Karolinska institutet, where he was a professor of pharmacology and a co-founder of Aerocrine AB.